Business Wire

The We Company Launches ARK A New Real Estate Acquisition & Management Platform

15.5.2019 14:00:00 EEST | Business Wire | Press release

Share

The We Company is pleased to announce the launch of ARK, its global real estate acquisition and management platform.

An Evolution of The We Company Real Estate Investment Strategy

ARK builds on the strong foundation in real estate acquisition and management represented by WeWork Property Advisors, an investment advisor affiliated with The We Company and Rhône Group and will combine with ARK as part of the launch.

ARK will focus on acquiring, developing, and managing real estate assets in global gateway cities and high-growth secondary markets that will benefit from WeWork’s occupancy. WeWork will deploy its space-as-a-service model in Ark owned or operated properties for our member companies, including our growing Enterprise business - now representing over 40% of global memberships - in conjunction with our anchor tenant strategy.

ARK will leverage its access to The We Company’s site selection process and proprietary technology, as well as its relationships with partners and enterprise member companies, to access a broad range of real estate opportunities. ARK intends to immediately stabilize assets by executing a proven pre-packaged business plan and will apply The We Company’s holistic solutions for real estate owners, based on The We Company’s established capabilities in sourcing, building, filling, and operating properties.

Rich Gomel, Managing Partner, ARK, said: “We have seen first hand the value that the WeWork ecosystem can create for landlords and real estate partners. The launch of ARK will help drive growth by leveraging The We Company’s extensive real estate experience and network. ARK has been set up to capitalize on that opportunity and allow us to provide different partnership options for the real estate community to participate in the growth and expansion of the We Company.”

Ivanhoé Cambridge - Strategic Partner

ARK is also pleased to announce that Ivanhoé Cambridge, a real estate subsidiary of Caisse de dépôt et placement du Québec and one of the world’s largest and most highly-respected institutional real estate investors, is providing substantial capital and support to the platform. Ivanhoé Cambridge plans to collaborate with ARK on its real estate acquisition and management of properties around the world, allowing the platform to benefit from Ivanhoé Cambridge’s significant experience and expertise in the real estate sector.

Sylvain Fortier, Chief Investment and Innovation Officer at Ivanhoé Cambridge said: “Like The We Company, we believe there is enormous upside in disrupting traditional norms of real estate. We share the same vision, commitment to social responsibility, and long-term approach towards real estate making this a natural partnership and one that we are confident will be transformational for both companies. The We Company brings its creative and innovative talent, along with its technological and design expertise, which are essential to meeting the new expectations of real estate spaces whether it is in the commercial or residential sphere. ARK brings a strong team of acquisition and asset management professionals and deep relationships with The We Company. I think we will complement each other beautifully.”

Management Team and Partners

ARK will initially deploy $2.9bn in total equity capital following its combination with WeWork Property Advisors. The We Company will be the majority owner of ARK.

The platform will be chaired by Steven Langman, Managing Director of Rhône Group and a member of The We Company’s Board of Directors. He will serve as Chairman of ARK’s Management Committee and will also serve on ARK’s investment committees.

In addition to Mr. Langman and Mr. Gomel, Wendy Silverstein, formerly of New York Reit and Vornado Realty Trust will serve as ARK’s Chief Investment Officer. ARK’s leadership is supported by a dedicated group of experienced real estate professionals with diverse expertise across real estate acquisition, development, and management.

About :

The We Company

Founded by Adam and Rebekah Neumann and Miguel McKelvey in 2010, The We Company comprises three distinct business lines - WeWork, WeLive, and WeGrow - that further our mission to elevate the world’s consciousness. WeWork’s mission is to create a world where people work to make a life, not just a living; WeLive’s mission is to build a world where no one feels alone; and WeGrow’s mission is to unleash every human’s superpowers. The We Company began 2019 with 425 locations in 100 cities across 27 countries, and has over 400,000 members, which includes over 30% of the Fortune 500. For additional information, please visit www.we.co

ARK

ARK is an affiliate of The We Company and serves as its new global real estate acquisition and management platform based in New York City. ARK’s focus is acquiring, developing, and managing select real estate assets in global gateway cities and high-growth secondary markets. ARK collaborates with The We Company to apply The We Company’s existing, new, and developing products and methods of community and space management to ARK-owned real estate and leverage The We Company’s relationships with partners and enterprise member companies to create vibrant fully-programmed ecosystems.

Notes :

This press release may contain forward-looking statements, which should not be relied upon, and may be changed. Nothing contained in this press release should be relied upon as a promise, guaranty, or representation as to past or future performance of any company, entity, or vehicle or other targeted outcome. Actual events and conditions may differ materially.

The activities described in this press release entail a high degree of risk and no assurance can be given that The We Company’s or ARK’s or any of their affiliates’ objectives will be achieved. Any targeted objectives described in this press release are hypothetical in nature and based on current beliefs, assumptions, and information, and are shown for illustrative informational purposes only and not intended to forecast or predict future events, which are subject to significant economic, market and other uncertainties. Equity capital managed by ARK is in certain instances co-managed in collaboration with other third-party institutional managers and is subject to the terms and conditions set out in the various definitive agreements relating to that equity capital. Nothing contained in this press release constitutes an offer to sell nor does it seek an offer to buy securities, or an offer of investment advisory or investment management services, in any jurisdiction.

Neither The We Company, ARK, nor any of their affiliates makes any representation or warranty, express or implied, as to the accuracy or completeness of the information contained in this press release. This press release is not an offer to sell nor does it seek an offer to buy securities in any jurisdiction. Recipients of this press release are encouraged to contact the representatives of The We Company and ARK to discuss the procedures and methodologies (including assumptions) on which these statements are based, and should conduct their own independent investigation and assessment and seek independent advice as to the validity of the information contained in this press release and its implications in light of their own particular circumstances.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Dominic McMullan / Arif Shah
press@wework.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye